IPOs Hot, but Ocera Chooses Reverse Merger to Go Public

The IPO window has turned into a sliding glass door with biotechs seizing the opportunity to tap the public markets. According to BioWorld Snapshots, 19 biotechs have hit the U.S. markets since the beginning of the year. And there are quite a few others building their books hoping to price in the coming weeks.